

University of Groningen

## Nutrition and biomarkers in psychiatry

Kemperman, Ramses Franciscus Jacobus

**IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from it. Please check the document version below.**

*Document Version*

Publisher's PDF, also known as Version of record

*Publication date:*

2007

[Link to publication in University of Groningen/UMCG research database](#)

*Citation for published version (APA):*

Kemperman, R. F. J. (2007). *Nutrition and biomarkers in psychiatry: research on micronutrient deficiencies in schizophrenia, the role of the intestine in the hyperserotonemia of autism, and a method for non-hypothesis driven discovery of biomarkers in urine.* s.n.

### Copyright

Other than for strictly personal use, it is not permitted to download or to forward/distribute the text or part of it without the consent of the author(s) and/or copyright holder(s), unless the work is under an open content license (like Creative Commons).

### Take-down policy

If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.

*Downloaded from the University of Groningen/UMCG research database (Pure): <http://www.rug.nl/research/portal>. For technical reasons the number of authors shown on this cover page is limited to 10 maximum.*

# Nutrition and Biomarkers in Psychiatry

*Research on micronutrient deficiencies in schizophrenia,  
the role of the intestine in the hyperserotonemia of autism,  
and a method for non-hypothesis driven discovery of biomarkers in urine*

Ramses F.J. Kemperman





**Rijksuniversiteit Groningen**

# Nutrition and Biomarkers in Psychiatry

Research on micronutrient deficiencies in schizophrenia, the role of the intestine in the hyperserotonemia of autism, and a method for non-hypothesis driven discovery of biomarkers in urine

## **Proefschrift**

ter verkrijging van het doctoraat in de  
Wiskunde en Natuurwetenschappen  
aan de Rijksuniversiteit Groningen  
op gezag van de  
Rector Magnificus, dr. F. Zwarts,  
in het openbaar te verdedigen op  
vrijdag 7 december 2007  
om 16.15 uur

door

**Ramses Franciscus Jacobus Kemperman**

geboren op 10 maart 1978  
te Nijmegen

**Promotores:** Prof. dr. F.A.J. Muskiet  
Prof. dr. R.P.H. Bischoff

**Copromotor:** Dr. I.P. Kema

**Beoordelingscommissie:** Prof. dr. H. Irth  
Prof. dr. J. Korf  
Prof. dr. ir. B.H.C. Westerink

**Paranimfen:** Theo Klein  
William Zuidland  
Dennis Kemperman

Het onderzoek beschreven in dit proefschrift is uitgevoerd aan de faculteit der Wiskunde en Natuurwetenschappen, Universitair Centrum voor Farmacie bij de basiseenheid Analytische Biochemie van de Rijksuniversiteit Groningen en de afdeling Pathologie en Laboratoriumgeneeskunde van het Universitair Medisch Centrum Groningen, te Groningen (NL). Het onderzoek is verricht binnen de onderzoeksschool Groningen University Institute for Drug Exploration (GUIDE).

**Sponsors:**

Het drukken van dit proefschrift werd mede mogelijk gemaakt door:

- Faculteit der Wiskunde en Natuurwetenschappen
- Rijksuniversiteit Groningen
- Groningen University Institute for Drug Exploration



University of Groningen



**Colofon:**

Opmaak: R.F.J. Kemperman, Groningen  
Omslag: C. Pet, Rheden; afgeleid van 'Cataract 3', 1967, van B. Riley en 'De Razernij', 17<sup>e</sup> eeuw, van G. Lamberts; LC-MS data in 3D.  
Drukkerij: Proefschriftmaken.nl, Uitgeverij BOX Press, Oisterwijk

© R.F.J. Kemperman, Groningen 2007

ISBN: 978-90-367-3220-8

ISBN: 978-90-367-3221-5 (electronic version)



# Contents

Scope, aim and outline of this thesis _____	13
---	----

## General Introduction

<b>Biomarker research in mental disorders; Linking biomarkers to etiology _____</b>	<b>17</b>
1. <i>Introduction</i> _____	20
2. <i>Epidemiology and economic costs</i> _____	22
3. <i>Diagnosis and classification</i> _____	24
3.1. Schizophrenia _____	25
3.2. Autism _____	26
4. <i>Etiology of schizophrenia and autism</i> _____	27
4.1. Psychological, Social and Cultural Risk Factors _____	29
4.2. Early-life events _____	32
4.3. Genetics and epigenetics of mental disorders _____	38
5. <i>Biomarkers for mental disorders</i> _____	57
5.1. Diagnostic biomarkers for mental disorders _____	58
5.2. Biomarkers for treatment monitoring of mental disorders _____	60
5.3. Biomarker discovery _____	60
5.4. Outlook and discussion _____	70
6. <i>Conclusion</i> _____	71

<b>Part I. Research on micronutrients in schizophrenia and the role of the intestine in the hyperserotonemia of autism _____</b>	<b>81</b>
--	-----------

## Chapter 1

<b>Folate and long chain polyunsaturated fatty acids in psychiatric disease _____</b>	<b>83</b>
1. <i>Introduction</i> _____	85
2. <i>Influence of genetics, birth weight and pregnancy complications</i> _____	86
3. <i>Nutritional factors in the etiology and severity of psychiatric disease</i> _____	87
4. <i>Folate, one-carbon metabolism and epigenetics</i> _____	88
5. <i>Long chain polyunsaturated fatty acids and brain development</i> _____	95



6. Schizophrenia-phospholipid hypothesis _____	96
7. Fish oil, schizophrenia and depression _____	98
8. Conclusions _____	98

## Chapter 2

### Low essential fatty acid and B-vitamin status in a subgroup of patients with schizophrenia and its response to dietary supplementation \_\_\_\_\_ 103

1. Introduction _____	105
2. Patients and Methods _____	106
2.1. Patients, samples and analyses _____	106
2.2. Supplementation of patients with poor B-vitamin and EFA status _____	107
2.3. Data evaluation and statistics _____	108
3. Results _____	109
3.1. Patients _____	109
3.2. Erythrocyte fatty acids _____	111
3.3. B-vitamins and homocysteine _____	114
3.4. Dietary supplementation _____	116
4. Discussion _____	118

## Chapter 3

### Brief Report: Normal intestinal permeability at elevated platelet serotonin levels in a subgroup of children with pervasive developmental disorders in Curaçao (The Netherlands Antilles) \_\_\_\_\_ 123

1. Introduction _____	125
2. Methods _____	126
2.1. Patients _____	126
2.2. Sugar Absorption Test _____	126
2.3. Serotonin Assays _____	127
2.4. Exclusion of Celiac Disease _____	127
2.5. Statistics _____	127
3. Results _____	128
3.1. Patients _____	128
3.2. Sugar Absorption Test _____	129
3.3. Serotonin Assays _____	129
3.4. Exclusion of Celiac Disease _____	130
3.5. Statistics _____	130
4. Discussion _____	130

## Chapter 4

### Relation between platelet serotonin and feeding mode in newborns suggests that gut motor activity is a determinant of platelet serotonin content \_\_\_\_\_ 133

1. Introduction _____	135
2. Materials and Methods _____	136
2.1. Patients and Samples _____	136
2.2. Analyses _____	137
2.3. Data evaluation and statistics _____	137
3. Results _____	138
3.1. Newborn and maternal indices and their interrelations _____	138
3.2. Relation between newborn PLT 5-HT and feeding mode _____	139
4. Discussion _____	141

## Part II. Comparative urine analysis for biomarker discovery \_\_\_\_\_ 145

### Chapter 5

#### Comparative Urine Analysis by Liquid Chromatography - Mass Spectrometry and Multivariate Statistics: Method Development, Evaluation and Application to Proteinuria \_\_\_\_\_ 147

1. Introduction _____	149
2. Experimental _____	151
2.1. Chemicals _____	151
2.2. Sample Preparation _____	151
2.3. Reversed Phase HPLC-MS _____	151
2.4. Tandem mass spectrometry and database searching _____	152
2.5. Data processing and analysis _____	153
3. Results _____	155
3.1. Method development and evaluation _____	155
3.2. Data processing and multivariate statistical analysis of LC-MS profiles of urinary compounds _____	159
4. Discussion and conclusion _____	169
4.1. Method development and evaluation _____	169
4.2. Data (pre-)processing and multivariate statistical comparison of LC-MS profiles of urinary compounds in different experimental settings _____	171

## Chapter 6

### Evaluation of a biomarker discovery platform for low-molecular weight urinary compounds: comparative analysis of urine from pregnant and non-pregnant females by liquid chromatography – mass spectrometry and multivariate statistical data analysis \_\_\_\_\_ 177

1. *Introduction* \_\_\_\_\_ 179
2. *Experimental* \_\_\_\_\_ 181
  - 2.1. Subjects: pregnant and non-pregnant females \_\_\_\_\_ 181
  - 2.2. Chemicals \_\_\_\_\_ 181
  - 2.3. Sample Preparation \_\_\_\_\_ 182
  - 2.4. Reversed Phase LC-MS analysis \_\_\_\_\_ 182
  - 2.5. Data processing and analysis \_\_\_\_\_ 183
3. *Results* \_\_\_\_\_ 185
  - 3.1. Evaluation of the normalization strategy and LC-MS system \_\_\_\_\_ 185
  - 3.2. Data processing and multivariate statistical analysis of LC-MS profiles \_\_\_\_\_ 187
4. *Discussion and conclusion* \_\_\_\_\_ 193

### Part III. Appendices \_\_\_\_\_ 199

### Summary and Future Perspectives \_\_\_\_\_ 201

### Samenvatting en Toekomstperspectief \_\_\_\_\_ 211

### Samenvatting voor de Leek \_\_\_\_\_ 223

### Dankwoord \_\_\_\_\_ 225

### Over de auteur \_\_\_\_\_ 231

### Lijst van publicaties \_\_\_\_\_ 233